TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.440
+0.140 (10.77%)
Apr 17, 2025, 4:00 PM EDT - Market closed
TScan Therapeutics Stock Forecast
TCRX's stock price has decreased by -79.8% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 9.83, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 582.64% from the current stock price of 1.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +525.00% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $10 | Buy | Initiates | $10 | +594.44% | Mar 14, 2025 |
| Barclays | Barclays | Buy Maintains $14 → $3 | Buy | Maintains | $14 → $3 | +108.33% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +941.67% | Mar 6, 2025 |
| Needham | Needham | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +525.00% | Mar 5, 2025 |
Financial Forecast
Revenue This Year
4.15M
from 2.82M
Increased by 47.30%
Revenue Next Year
7.23M
from 4.15M
Increased by 74.30%
EPS This Year
-1.20
from -2.25
EPS Next Year
-1.28
from -1.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 22.1M | 227.8M | ||
| Avg | 4.1M | 7.2M | 59.9M | ||
| Low | 2.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 272.9% | 431.6% | 3,050.6% | ||
| Avg | 47.3% | 74.3% | 728.6% | ||
| Low | -30.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.95 | -0.26 | ||
| Avg | -1.20 | -1.28 | -0.89 | ||
| Low | -1.30 | -1.86 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.